Agents for use in treating drug resistant tumors and triple negative breast cancer

Combination therapies comprising an agent which downregulates an amount and/or activity of a receptor which is expressed on the surface of tumor cells of a subject and an agent which specifically downregulates an amount and/or activity of at least one member of the Fak family for use in treating cancer, more specifically breast cancer, and most specifically triple negative breast cancer, are disclosed. Pharmaceutical compositions comprising the agents of the combination therapies are also disclosed, as well as an ex vivo method of predicting prognosis of triple negative breast cancer, and a kit for determining said prognosis.